Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing ; volume:19 ; number:1 ; day:5 ; month:7 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (5.7.2019), 1-10, 12.2019

Creator: Lokhandwala, Parvez M.
Tseng, Li-Hui
Rodriguez, Erika
Zheng, Gang
Pallavajjalla, Aparna
Gocke, Christopher D.
Eshleman, James R.
Lin, Ming-Tseh

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-019-5864-1

URN: urn:nbn:de:101:1-2019121104423470585420

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:04 PM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lokhandwala, Parvez M.
Tseng, Li-Hui
Rodriguez, Erika
Zheng, Gang
Pallavajjalla, Aparna
Gocke, Christopher D.
Eshleman, James R.
Lin, Ming-Tseh
SpringerLink (Online service)

Other Objects (12)

Targeted Therapy for Melanomas Without BRAF V600 Mutations

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Hochschulschrift

Mutational analysis in patients with uveal melanomas

Variations of BRAF mutant allele percentage in melanomas

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Targeted Therapy for Melanomas Without BRAF V600 Mutations

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Hochschulschrift

Mutational analysis in patients with uveal melanomas

Variations of BRAF mutant allele percentage in melanomas

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Targeted Therapy for Melanomas Without BRAF V600 Mutations

$Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas$

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Hochschulschrift

Mutational analysis in patients with uveal melanomas

Variations of BRAF mutant allele percentage in melanomas

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Mutational analysis in patients with uveal melanomas

Variations of BRAF mutant allele percentage in melanomas

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Mutational analysis in patients with uveal melanomas

Variations of BRAF mutant allele percentage in melanomas

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Targeted Therapy for Melanomas Without BRAF V600 Mutations

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF

Mutational analysis in patients with uveal melanomas

Variations of BRAF mutant allele percentage in melanomas

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing

BRAF fusions identified in melanomas have variable treatment responses and phenotypes

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models

Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group

Related objects

Reset password